Cargando…

Safety and Efficacy of an Oncolytic Adenovirus as an Immunotherapy for Canine Cancer Patients

SIMPLE SUMMARY: The use of oncolytic virus is an innovative approach that has shown promising results as a treatment in oncology. Epithelial-derived tumors are the most frequent neoplasms in dogs, but gold standard therapies can be highly invasive procedures. Due to the accessible localization of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Martín-Carrasco, Clara, Delgado-Bonet, Pablo, Tomeo-Martín, Beatriz Davinia, Pastor, Josep, de la Riva, Claudia, Palau-Concejo, Paula, del Castillo, Noemí, García-Castro, Javier, Perisé-Barrios, Ana Judith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316846/
https://www.ncbi.nlm.nih.gov/pubmed/35878344
http://dx.doi.org/10.3390/vetsci9070327
_version_ 1784754914060140544
author Martín-Carrasco, Clara
Delgado-Bonet, Pablo
Tomeo-Martín, Beatriz Davinia
Pastor, Josep
de la Riva, Claudia
Palau-Concejo, Paula
del Castillo, Noemí
García-Castro, Javier
Perisé-Barrios, Ana Judith
author_facet Martín-Carrasco, Clara
Delgado-Bonet, Pablo
Tomeo-Martín, Beatriz Davinia
Pastor, Josep
de la Riva, Claudia
Palau-Concejo, Paula
del Castillo, Noemí
García-Castro, Javier
Perisé-Barrios, Ana Judith
author_sort Martín-Carrasco, Clara
collection PubMed
description SIMPLE SUMMARY: The use of oncolytic virus is an innovative approach that has shown promising results as a treatment in oncology. Epithelial-derived tumors are the most frequent neoplasms in dogs, but gold standard therapies can be highly invasive procedures. Due to the accessible localization of these tumors, the intratumoral administration is feasible. Therefore, we propose to determine the safety and efficacy of intratumoral administration of oncolytic adenovirus ICOCAV15, in canine patients with epithelial-derived tumors. Eight dogs with carcinoma/adenocarcinoma were intratumorally treated with ICOCAV15. No clinically relevant changes were observed in the blood count, biochemistry and coagulation test analyzed during follow-up. The survival time of the 6/8 dogs exceeded the median survival time with chemotherapy, showing a partial response rate of 25% and 75% of stable disease. ICOCAV15 was detected in the target lesion by qPCR and immunohistochemistry. Also, some of the non-treated metastasis showed an infiltration of ICOCAV15 by immunohistochemistry. The immune populations were evaluated, and an increase of CD8+, MAC387+, CD3+ and CD20+ cells was reported in some of the patients after the inoculation. These results show that intratumoral ICOCAV15 is safe and well tolerated by dogs. Also, they suggest ICOCAV15 could be a new tool in veterinary oncology for accessible carcinomas/adenocarcinomas. ABSTRACT: The use of oncolytic viruses is an innovative approach to lyse tumor cells and induce antitumor immune responses. Eight dogs diagnosed with carcinoma/adenocarcinoma were intratumorally treated with ICOCAV15, an oncolytic canine adenovirus (CAV). To evaluate the treatment’s safety, a blood count, biochemistry, and coagulation test were performed before treatment and during follow-up. Immune populations were analyzed by flow cytometry. Anti-adenovirus antibodies were also determined. The immune infiltration, vascularization, and viral presence in the tumor were determined by CD3, CD4, CD20, CD31 and CAV by immunohistochemistry. All the dogs maintained a good quality of life during follow-up, and some had increased median survival time when compared with dogs treated with chemotherapy. No treatment-related adverse effects were detected. The Response Evaluation Criteria In Solid Tumors criteria were also assessed: two patients showed a partial response and the rest showed stable disease at various times during the study. ICOCAV15 was detected inside the tumor during follow-up, and antiviral antibodies were detected in all patients. Furthermore, the tumor-infiltrating immune cells increased after viral administration. Therefore, we suggest that intratumorally administered ICOCAV15 could represent as a new tool for the treatment of canine carcinoma because it is safe, well-tolerated by dogs, and shows promising results.
format Online
Article
Text
id pubmed-9316846
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93168462022-07-27 Safety and Efficacy of an Oncolytic Adenovirus as an Immunotherapy for Canine Cancer Patients Martín-Carrasco, Clara Delgado-Bonet, Pablo Tomeo-Martín, Beatriz Davinia Pastor, Josep de la Riva, Claudia Palau-Concejo, Paula del Castillo, Noemí García-Castro, Javier Perisé-Barrios, Ana Judith Vet Sci Article SIMPLE SUMMARY: The use of oncolytic virus is an innovative approach that has shown promising results as a treatment in oncology. Epithelial-derived tumors are the most frequent neoplasms in dogs, but gold standard therapies can be highly invasive procedures. Due to the accessible localization of these tumors, the intratumoral administration is feasible. Therefore, we propose to determine the safety and efficacy of intratumoral administration of oncolytic adenovirus ICOCAV15, in canine patients with epithelial-derived tumors. Eight dogs with carcinoma/adenocarcinoma were intratumorally treated with ICOCAV15. No clinically relevant changes were observed in the blood count, biochemistry and coagulation test analyzed during follow-up. The survival time of the 6/8 dogs exceeded the median survival time with chemotherapy, showing a partial response rate of 25% and 75% of stable disease. ICOCAV15 was detected in the target lesion by qPCR and immunohistochemistry. Also, some of the non-treated metastasis showed an infiltration of ICOCAV15 by immunohistochemistry. The immune populations were evaluated, and an increase of CD8+, MAC387+, CD3+ and CD20+ cells was reported in some of the patients after the inoculation. These results show that intratumoral ICOCAV15 is safe and well tolerated by dogs. Also, they suggest ICOCAV15 could be a new tool in veterinary oncology for accessible carcinomas/adenocarcinomas. ABSTRACT: The use of oncolytic viruses is an innovative approach to lyse tumor cells and induce antitumor immune responses. Eight dogs diagnosed with carcinoma/adenocarcinoma were intratumorally treated with ICOCAV15, an oncolytic canine adenovirus (CAV). To evaluate the treatment’s safety, a blood count, biochemistry, and coagulation test were performed before treatment and during follow-up. Immune populations were analyzed by flow cytometry. Anti-adenovirus antibodies were also determined. The immune infiltration, vascularization, and viral presence in the tumor were determined by CD3, CD4, CD20, CD31 and CAV by immunohistochemistry. All the dogs maintained a good quality of life during follow-up, and some had increased median survival time when compared with dogs treated with chemotherapy. No treatment-related adverse effects were detected. The Response Evaluation Criteria In Solid Tumors criteria were also assessed: two patients showed a partial response and the rest showed stable disease at various times during the study. ICOCAV15 was detected inside the tumor during follow-up, and antiviral antibodies were detected in all patients. Furthermore, the tumor-infiltrating immune cells increased after viral administration. Therefore, we suggest that intratumorally administered ICOCAV15 could represent as a new tool for the treatment of canine carcinoma because it is safe, well-tolerated by dogs, and shows promising results. MDPI 2022-06-28 /pmc/articles/PMC9316846/ /pubmed/35878344 http://dx.doi.org/10.3390/vetsci9070327 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Martín-Carrasco, Clara
Delgado-Bonet, Pablo
Tomeo-Martín, Beatriz Davinia
Pastor, Josep
de la Riva, Claudia
Palau-Concejo, Paula
del Castillo, Noemí
García-Castro, Javier
Perisé-Barrios, Ana Judith
Safety and Efficacy of an Oncolytic Adenovirus as an Immunotherapy for Canine Cancer Patients
title Safety and Efficacy of an Oncolytic Adenovirus as an Immunotherapy for Canine Cancer Patients
title_full Safety and Efficacy of an Oncolytic Adenovirus as an Immunotherapy for Canine Cancer Patients
title_fullStr Safety and Efficacy of an Oncolytic Adenovirus as an Immunotherapy for Canine Cancer Patients
title_full_unstemmed Safety and Efficacy of an Oncolytic Adenovirus as an Immunotherapy for Canine Cancer Patients
title_short Safety and Efficacy of an Oncolytic Adenovirus as an Immunotherapy for Canine Cancer Patients
title_sort safety and efficacy of an oncolytic adenovirus as an immunotherapy for canine cancer patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316846/
https://www.ncbi.nlm.nih.gov/pubmed/35878344
http://dx.doi.org/10.3390/vetsci9070327
work_keys_str_mv AT martincarrascoclara safetyandefficacyofanoncolyticadenovirusasanimmunotherapyforcaninecancerpatients
AT delgadobonetpablo safetyandefficacyofanoncolyticadenovirusasanimmunotherapyforcaninecancerpatients
AT tomeomartinbeatrizdavinia safetyandefficacyofanoncolyticadenovirusasanimmunotherapyforcaninecancerpatients
AT pastorjosep safetyandefficacyofanoncolyticadenovirusasanimmunotherapyforcaninecancerpatients
AT delarivaclaudia safetyandefficacyofanoncolyticadenovirusasanimmunotherapyforcaninecancerpatients
AT palauconcejopaula safetyandefficacyofanoncolyticadenovirusasanimmunotherapyforcaninecancerpatients
AT delcastillonoemi safetyandefficacyofanoncolyticadenovirusasanimmunotherapyforcaninecancerpatients
AT garciacastrojavier safetyandefficacyofanoncolyticadenovirusasanimmunotherapyforcaninecancerpatients
AT perisebarriosanajudith safetyandefficacyofanoncolyticadenovirusasanimmunotherapyforcaninecancerpatients